Should I buy or sell Sanara MedTech stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SMTI shares. View SMTI analyst ratings or view top-rated stocks .

What is Sanara MedTech's stock price target for 2024?

1 Wall Street analysts have issued twelve-month price objectives for Sanara MedTech's stock. Their SMTI share price targets range from $49.00 to $49.00. On average, they predict the company's stock price to reach $49.00 in the next year. This suggests a possible upside of 48.8% from the stock's current price. View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts .

How have SMTI shares performed in 2023?

Sanara MedTech's stock was trading at $45.50 at the beginning of the year. Since then, SMTI shares have decreased by 27.6% and is now trading at $32.93. View the best growth stocks for 2023 here .

When is Sanara MedTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our SMTI earnings forecast .

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) announced its earnings results on Monday, November, 13th. The company reported ($0.13) earnings per share (EPS) for the quarter. The business earned $16.03 million during the quarter. Sanara MedTech had a negative net margin of 13.05% and a negative trailing twelve-month return on equity of 20.51%.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE) , Ovintiv (OVV) , SIG (SHI) , Zynerba Pharmaceuticals (ZYNE) , AbbVie (ABBV) , American Airlines Group (AAL) , Abbott Laboratories (ABT) , Aurora Cannabis (ACB) , AC Immune (ACIU) and Applied Genetic Technologies (AGTC) .

Who are Sanara MedTech's major shareholders?

Sanara MedTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.36%), Quadrature Capital Ltd (0.18%), Janney Montgomery Scott LLC (0.13%), Lazard Asset Management LLC (0.03%), New York State Common Retirement Fund (0.03%) and UBS Group AG (0.03%). Insiders that own company stock include Shawn M Bowman and Zachary B Fleming . View institutional ownership trends .

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Sanara MedTech Stock Price, News & Analysis (NASDAQ:SMTI)

$32.93

-0.27 (-0.81%)

(As of 12/6/2023 ET)

Compare

Today's Range: $31.99
▼
$33.62
50-Day Range: $26.33
▼
$34.10
52-Week Range: $26.06
▼
$50.18

Volume: 15,330 shs
Average Volume: 16,089 shs
Market Capitalization: $281.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.00

Sanara MedTech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 48.8% Upside
$49.00 Price Target
Short Interest: Healthy
3.43% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.19
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.70) to $0.52 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

245th out of 957 stocks

Surgical Appliances & Supplies Industry

9th out of 18 stocks

3.5

Analyst's Opinion

Consensus Rating
Sanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.00, Sanara MedTech has a forecasted upside of 48.8% from its current price of $32.93.
Amount of Analyst Coverage
Sanara MedTech has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.43% of the float of Sanara MedTech has been sold short.
Short Interest Ratio / Days to Cover
Sanara MedTech has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in Sanara MedTech has recently decreased by 9.72%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sanara MedTech does not currently pay a dividend.
Dividend Growth
Sanara MedTech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SMTI.

3.4

News and Social Media Coverage

News Sentiment
Sanara MedTech has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sanara MedTech this week, compared to 0 articles on an average week.
Search Interest
8 people have searched for SMTI on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sanara MedTech insiders have not sold or bought any company stock.
Percentage Held by Insiders
55.20% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.83% of the stock of Sanara MedTech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sanara MedTech are expected to grow in the coming year, from ($0.70) to $0.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sanara MedTech is -32.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sanara MedTech is -32.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sanara MedTech has a P/B Ratio of 6.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sanara MedTech Stock (NASDAQ:SMTI)

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

SMTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SMTI Stock News Headlines

December 4, 2023 | finance.yahoo.com

Sanara MedTech Inc.'s (NASDAQ:SMTI) top owners are retail investors with 32% stake, while 31% is held by insiders

November 30, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 15, 2023 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q3 2023 Earnings Call Transcript

November 13, 2023 | msn.com

Sanara MedTech GAAP EPS of -$0.13, revenue of $16M misses by $2.8M

November 13, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces Third Quarter 2023 Results

November 13, 2023 | finance.yahoo.com

Sanara MedTech Inc. Reports Record Sales in Q3 2023 with Narrowed Net Loss and Positive ...

November 12, 2023 | morningstar.com

Sanara MedTech Inc SMTI

December 7, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 30, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates

October 10, 2023 | finance.yahoo.com

Sanara MedTech Announces First Sale of ALLOCYTE® Plus Advanced Viable Bone Matrix and Provides Other Product Updates

October 5, 2023 | finance.yahoo.com

Sanara MedTech's (NASDAQ:SMTI) investors will be pleased with their incredible 516% return over the last five years

September 13, 2023 | msn.com

Sanara MedTech: Surgical Sales Set To Accelerate While Post Acute Care Platform Develops

September 12, 2023 | finance.yahoo.com

Sanara MedTech to Participate in Two Upcoming Conferences

August 31, 2023 | finance.yahoo.com

We're Not Very Worried About Sanara MedTech's (NASDAQ:SMTI) Cash Burn Rate

August 18, 2023 | msn.com

Cantor Fitzgerald Reiterates Sanara MedTech (SMTI) Overweight Recommendation

August 14, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces Second Quarter 2023 Results

August 2, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces the Acquisition of Certain Assets Related to its Collagen Products Business

August 1, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates

July 24, 2023 | finance.yahoo.com

Sanara MedTech Inc.'s (NASDAQ:SMTI) Path To Profitability

July 15, 2023 | finance.yahoo.com

SMTI - Sanara MedTech Inc.

June 27, 2023 | finance.yahoo.com

Sanara MedTech Inc.'s (NASDAQ:SMTI) largest shareholders are individual investors with 32% ownership, insiders own 32%

June 14, 2023 | msn.com

Sanara MedTech: Qualified Growth Company, Market Selloff Unjustified

May 24, 2023 | msn.com

Down -14.23% in 4 Weeks, Here's Why Sanara MedTech Inc. (SMTI) Looks Ripe for a Turnaround

May 15, 2023 | msn.com

Sanara MedTech: Q1 Earnings Insights

May 15, 2023 | finance.yahoo.com

Sanara MedTech Inc. Announces First Quarter 2023 Results

May 5, 2023 | finance.yahoo.com

Sanara MedTech Inc.'s (NASDAQ:SMTI) Price In Tune With Revenues

See More Headlines

Receive SMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SMTI
CUSIP: N/A
CIK: 714256
Web: www.wndm.com
Phone: (817) 529-2300
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $49.00
High Stock Price Target: $49.00
Low Stock Price Target: $49.00
Potential Upside/Downside: +47.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,940,000.00
Net Margins: -13.05%
Pretax Margin: -13.32%
Return on Equity: -20.51%
Return on Assets: -13.54%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 1.46
Quick Ratio: 1.09

Sales & Book Value

Annual Sales: $45.84 million
Price / Sales: 6.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.02 per share
Price / Book: 6.60

Miscellaneous

Outstanding Shares: 8,540,000
Free Float: 3,825,000
Market Cap: $283.10 million
Optionable: Not Optionable
Beta: 1.75

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Ronald T. Nixon (Age 67)
Executive Chairman
Mr. Zachary B. Fleming (Age 48)
Chief Executive Officer
Comp: $593.64k
Mr. Michael D. McNeil (Age 58)
CFO & Corporate Secretary
Comp: $438.68k
Dr. Christopher A. Morrison FACHM (Age 53)
FAPWCA, FCCWS, M.D., President of Telehealth Services
Comp: $156k
Mr. Callon Nichols
Vice President of Corporate Operations
Mr. Bill Fitzgerald
Chief Compliance Officer
Ms. Tricia Matteson
Vice President of Marketing
Dr. Rebecca Erin Mcmahon (Age 38)
President of Research & Development
Mr. Ryan Phillips
President of Biologics
Mr. Seth Yon
President of Commercial

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SMTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanara MedTech stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SMTI shares.
View SMTI analyst ratings or view top-rated stocks.
What is Sanara MedTech's stock price target for 2024?: 1 Wall Street analysts have issued twelve-month price objectives for Sanara MedTech's stock. Their SMTI share price targets range from $49.00 to $49.00. On average, they predict the company's stock price to reach $49.00 in the next year. This suggests a possible upside of 48.8% from the stock's current price.
View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts.
How have SMTI shares performed in 2023?: Sanara MedTech's stock was trading at $45.50 at the beginning of the year. Since then, SMTI shares have decreased by 27.6% and is now trading at $32.93.
View the best growth stocks for 2023 here.
When is Sanara MedTech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our SMTI earnings forecast.

How were Sanara MedTech's earnings last quarter?: Sanara MedTech Inc. (NASDAQ:SMTI) announced its earnings results on Monday, November, 13th. The company reported ($0.13) earnings per share (EPS) for the quarter. The business earned $16.03 million during the quarter. Sanara MedTech had a negative net margin of 13.05% and a negative trailing twelve-month return on equity of 20.51%.
What other stocks do shareholders of Sanara MedTech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), Aurora Cannabis (ACB), AC Immune (ACIU) and Applied Genetic Technologies (AGTC).
Who are Sanara MedTech's major shareholders?: Sanara MedTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.36%), Quadrature Capital Ltd (0.18%), Janney Montgomery Scott LLC (0.13%), Lazard Asset Management LLC (0.03%), New York State Common Retirement Fund (0.03%) and UBS Group AG (0.03%). Insiders that own company stock include Shawn M Bowman and Zachary B Fleming.
View institutional ownership trends.
How do I buy shares of Sanara MedTech?: Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SMTI) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial